Benjamin L. Palleiko Sells 14,400 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the transaction, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

KalVista Pharmaceuticals Price Performance

KALV opened at $9.28 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.39 and a 12-month high of $16.88. The stock has a market capitalization of $400.82 million, a PE ratio of -2.63 and a beta of 0.92. The firm’s fifty day moving average price is $11.04 and its 200 day moving average price is $11.99.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.04. On average, equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on KALV. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of KALV. Vestal Point Capital LP grew its position in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares during the last quarter. Capital World Investors bought a new position in KalVista Pharmaceuticals during the 1st quarter worth $17,370,000. Great Point Partners LLC bought a new stake in KalVista Pharmaceuticals in the second quarter valued at $15,768,000. State Street Corp boosted its holdings in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the period. Finally, Emerald Advisers LLC grew its position in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after acquiring an additional 192,091 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).